Haemonetics Corporation
HAE
$78.71
$3.835.12%
NYSE
| 03/28/2026 | 12/27/2025 | 09/27/2025 | 06/28/2025 | 03/29/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.33B | 1.32B | 1.33B | 1.35B | 1.36B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.33B | 1.32B | 1.33B | 1.35B | 1.36B |
| Cost of Revenue | 546.97M | 530.31M | 545.65M | 567.25M | 594.60M |
| Gross Profit | 787.06M | 787.96M | 782.20M | 778.80M | 766.23M |
| SG&A Expenses | 431.25M | 421.59M | 421.41M | 426.35M | 427.77M |
| Depreciation & Amortization | 44.00M | 44.80M | 46.10M | 47.18M | 48.26M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.08B | 1.06B | 1.08B | 1.10B | 1.13B |
| Operating Income | 253.02M | 260.48M | 252.06M | 243.02M | 229.06M |
| Income Before Tax | 128.03M | 227.17M | 217.11M | 210.53M | 212.07M |
| Income Tax Expenses | 30.72M | 51.73M | 48.92M | 47.19M | 44.39M |
| Earnings from Continuing Operations | 97.31 | 175.44 | 168.19 | 163.34 | 167.68 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 97.31M | 175.44M | 168.19M | 163.34M | 167.68M |
| EBIT | 253.02M | 260.48M | 252.06M | 243.02M | 229.06M |
| EBITDA | 358.64M | 366.39M | 359.60M | 351.53M | 337.94M |
| EPS Basic | 2.04 | 3.65 | 3.44 | 3.30 | 3.34 |
| Normalized Basic EPS | 2.90 | 3.09 | 2.90 | 2.74 | 2.72 |
| EPS Diluted | 2.02 | 3.64 | 3.43 | 3.28 | 3.32 |
| Normalized Diluted EPS | 2.89 | 3.08 | 2.89 | 2.73 | 2.70 |
| Average Basic Shares Outstanding | 188.72M | 191.69M | 195.18M | 198.49M | 201.32M |
| Average Diluted Shares Outstanding | 189.23M | 192.48M | 196.13M | 199.71M | 202.92M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |